- -
-
Sažetak
-
Reference
References
1. Li T, Zhu J, Fang Q, Duan X, Zhang M, Diao S, Zhou Y, Yang S, Kong Y, Cai X. Association of H-type hypertension with stroke severity and prognosis. Biomed Res Int, 2018;2018:8725908(1-8).
2. Li T, Liu X, Diao S, Kong Y, Duan X, Yang S, Liu S, Fang Q, Cai X. H-type hypertension is a risk factor for cerebral small-vessel disease. Biomed Res Int, 2020;2020:6498903(1-6).
3. Wu Z, Li ZR, Dai YQ, Zhu FY, Tan JX, Wan LH. Relationship between risk perception and lifestyle in ischemic stroke patients with H-type hypertension. Ann Palliat Med, 2020;9(6):3731-3741.
4. Qiao J, Zhou K, Huang C, Fu S, Xing Y, Zhang B. Comparison of serum Lp-PLA2 levels in ischemic stroke patients with H-type hypertension or non-H-type hypertension. J Clin Lab Anal, 2020;34(2):e23068(1-7).
5. Zhang J, Liu Y, Wang A, Wang D, Jiang R, Jia J, Chen S, Zhao X. Association between H-type hypertension and asymptomatic extracranial artery stenosis. Sci Rep, 2018;8(1):1328(1-6).
6. Chen D, Li C, Cai H, Zhuang J, Huang Y, Peng X, Li S, Huang Y, Wang P, Luo Y, Zhan Z. Effect of banxia baizhu tianma tang for H-type hypertension: a protocol for a systematic review. Medicine (Baltimore), 2020;99(9):e19309(1-4).
7. Huang LQ, Wu CX, Wei HQ, Xu G. Clinical characteristics of H-type hypertension and its relationship with the MTHFR C677T polymorphism in a Zhuang population from Guangxi, China. J Clin Lab Anal, 2020;34(11):e23499(1-5).
8. Li M, Zhan A, Huang X, Hu L, Zhou W, Wang T, Zhu L, Bao H, Cheng X. Positive association between triglyceride glucose index and arterial stiffness in hypertensive patients: the China H-type Hypertension Registry Study. Cardiovasc Diabetol, 2020;19(1):139(1-17).
9. Chen YN, Wei P, Yu Bs J. Higher concentration of serum C-terminal cross-linking telopeptide of type I collagen is positively related with inflammatory factors in postmenopausal women with H-type hypertension and osteoporosis. Orthop Surg, 2019;11(6):1135-1141.
10. Zhou F, Hou D, Wang Y, Yu D. Evaluation of H-type hypertension prevalence and its influence on the risk of increased carotid intima-media thickness among a high-risk stroke population in Hainan Province, China. Medicine (Baltimore), 2020;99(35):e21953(1-6).
11. Goswami AM. Computational analyses prioritize and reveal the deleterious nsSNPs in human angiotensinogen gene. Comput Biol Chem, 2020;84:107199(1-12).
12. Yu SJ, Peng WJ, Zhang H, Chen XZ, Wei MH, Yan WR. Association between both maternal and fetal angiotensinogen gene single nucleotide polymorphism and preeclampsia/eclampsia. Zhonghua Liu Xing Bing Xue Za Zhi, 2019;40(8):997-1002.
13. Wang H, Zhang K, Qin H, Yang L, Zhang L, Cao Y. Genetic association between angiotensinogen polymorphisms and lung cancer risk. Medicine (Baltimore), 2015;94(37):e1250(1-6).
14. Zhai C, Cong H, Zhang H, Hou K, Zhang Y, Zhang Y. M235T polymorphism in the angiotensinogen gene and cardiovascular disease: an updated meta-analysis of 39 case-control comparisons. Anatol J Cardiol, 2019;21(4):222-232.
15. Papaggelopoulos J, Angelopoulou A, Avgoustidis D, Koronellos N, Derka S, Vassiliou S, Yapijakis C. Association of polymorphisms in the genes of angiotensinogen and angiotensin receptors with risk for basal cell carcinoma. Anticancer Res, 2019;39(10):5525-5530.
16. Alaee E, Mirahmadi M, Ghasemi M, Kashani E, Attar M, Shahbazi M. Association study of M235T and A-6G polymorphisms in angiotensinogen gene with risk of developing preeclampsia in Iranian population. Ann Hum Genet, 2019;83(6):418-425.
17. Chen S, Zhang L, Wang HW, Wang XY, Li XQ, Zhang LL. The m235t polymorphism in the angiotensinogen gene and heart failure: a meta-analysis. J Renin Angiotensin Aldosterone Syst, 2015;15(2):647-652.
18. Mopidevi B, Kaw MK, Sivankutty I, Jain S, Perla SK, Kumar A. A polymorphism in intron I of the human angiotensinogen gene (hAGT) affects binding by HNF3 and hAGT expression and increases blood pressure in mice. J Biol Chem, 2019;294(31):11829-11839.
19. Hyun K, Jeon J, Park K, Kim J. Writing, erasing and reading histone lysine methylations. Exp Mol Med, 2017;49(4):e324(1-22).
20. Liu Y, Liu Z, Tang H, Shen Y, Gong Z, Xie N, Zhang X, Wang W, Kong W, Zhou Y, Fu Y. The N6-methyladenosine (m6A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STAT1 mRNA. Am J Physiol Cell Physiol, 2019;317(4):C762-C775.
21. Clark WC, Evans ME, Dominissini D, Zheng G, Pan T. tRNA base methylation identification and quantification via high-throughput sequencing. RNA, 2016;22(11):1771-1784.
22. Maeda N, Funahashi T, Matsuzawa Y, Shimomura I. Adiponectin, a unique adipocyte-derived factor beyond hormones. Atherosclerosis, 2020;292:1-9.
23. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest, 2006;116(7):1784-1792.
24. Lee JY, Yang JW, Han BG, Choi SO, Kim JS. Adiponectin for the treatment of diabetic nephropathy. Korean J Intern Med, 2019;34(3):480-491.
25. Yanai H, Yoshida H. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives. Int J Mol Sci, 2019;20(5):1190(1-25).
26. Liu H, Wu X, Luo J, Zhao L, Li X, Guo H, Bai H, Cui W, Guo W, Feng D, Qu Y. Adiponectin peptide alleviates oxidative stress and NLRP3 inflammasome activation after cerebral ischemia-reperfusion injury by regulating AMPK/GSK-3β. Exp Neurol, 2020;329:113302(1-15).
27. Kai H. Hypertension: the points of management of hypertensions--based on the JSH 2014 hypertension guidelines--. topics: IV. Treatment for hypertension associated with cerebrovascular disease/heart disease. Nihon Naika Gakkai Zasshi, 2015;104(2):232-239.
28. Liao CT, Wu PC, Shih JC, Cheng TJ, Wu WS. Higher hypertension prevalence, lower incidence, and aggressive treatment with decreasing mortality, cardiovascular, and cerebrovascular incidence in Taiwan from 2005 to 2010: a 2 population-based cohorts study. Medicine (Baltimore), 2020;99(39):e22437(1-7).
Sva prava zadržana (c) 2024 Shangyu Wen
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.